The global GLP-1 pharmaceutical market alone was valued at $53.46 billion in 2024 and is projected to grow at a CAGR of 17.5% from 2025 to 2030, reaching approximately $156.71 billion by 2030**
If cost is a concern, patients should discuss all available options with their healthcare provider, including exploring more affordable access through Universal Drugstore for cash-pay pricing
Third-party testing from ISO 17025 accredited laboratories provides unbiased quality data
BOMSS recommends a comprehensive blood monitoring panel that typically includes full blood count, urea and electrolytes, liver function tests, ferritin, folate, vitamin B12, vitamin D, calcium, and parathyroid hormone (PTH)
Both factors are predictors of the poor response to H1AH and even to omalizumab